Skip to main content

Table 1 Long-term follow-up analysis

From: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer

Individual patient number

Cancer stage prior to treatment

1 year

1.5 year

2 years

3 years

TNM

AJCC

    

Panagen group

02-01

T4NxM0

IIIB

ND1

Alive

Alive

Progression. Metastases in lungs

02-02

T2N0M0

IIA

Remission

Remission

Remission

ND

02-03

T1N1M0

IIA

Remission

Remission

Remission

Progression. Metastases in Th11

02-04

T3N2M1

IV

Deceased. Cause: breast cancer

-

-

-

02-05

T4N1M0

IIIB

Remission

Remission

Remission

ND

02-06

T4NxM1

IV

Deceased. Cause: breast cancer

-

-

-

02-08

T4N1M0

IIIB

Remission

Remission

Remission

ND

02-09

T1N1M0

IIA

Progression. Bone metastases (detected after 1st chemotherapy)

Alive

Alive

ND

02-10

T1N1M0

IIA

Remission

Remission

Remission

Remission

02-11*

T2N1M0

IIB

Remission

Remission

Remission

Remission

02-14

T2N2M0dex T4N1M0sin

IIIB

Remission

Remission

Remission

Remission

02-15

T3N2M0

IIIA

Remission

Remission

Remission

Remission

02-16*

T4NxM0

IIIB

Remission

Cancer relapse. Skin metastases around scar tissue

Partial regression

ND

02-18*

T4NxM0

IIIB

ND

Alive

Alive

ND

02-20

T2N1M0

IIB

Remission

Remission

Remission

 

02-21

T2N0M0

IIA

Remission

Remission

Remission

 

02-22*

T2N1M0

IIB

Remission

Remission

Remission

 

02-24

T2N1M0

IIB

Remission

Remission

Remission

 

02-25*

T2N2M0

IIIA

Remission

Remission

Remission

 

02-26

T1N1M0

IIA

Remission

Remission

Remission

 

02-27

T1N2M0

IIIA

Remission

Remission

ND

 

02-28*

T2N1M0

IIB

Remission

Remission

ND

 

02-29

T2N0M0

IIA

Remission

Remission

ND

 

02-30

T2NxM0

II

Remission

Remission

Remission

 

02-31

T2N1M0

IIB

Progression. Metastases in lungs

Alive

Alive

 

02-33*

T2N3M0

IIIC

Remission

ND

ND

 

02-36

T4NxM0dex T2NxM0sin

IIIB

Treatment is on-going due to chemotherapy scheduling issues

Treatment in progress

ND

 

02-39

T2N3M0

IIIC

Remission

Remission

Remission

 

02-40*

T2N1M0

IIB

Remission

ND

ND

 

02-42*

T1N3M0

IIIC

Remission

Remission

Remission

 

02-43

T3N0M0

IIB

Remission

Remission

Remission

 

02-44*

T1N1M0

IIA

Progression. Bone metastases (detected after 2nd chemotherapy)

ND

ND

 

02-45*

T4N1M0

IIIB

Remission

Remission

Remission

 

Final outcome

Progression or death in 8 out of 33 patients (24%)

  

Placebo group

02-07

T4N2M0

IIIB

Deceased. Cause: breast cancer

-

-

-

02-12*

T2N2M0

IIIA

Remission

Remission

Remission

ND

02-13

T4N3M0

IIIC

Treatment in progress

Progression. Metastases in lungs

ND

ND

02-17

T2N1M0

IIB

Remission

Remission

Remission

Remission

02-23*

T2N1M0

IIB

Progression. Bone metastases

Alive

ND

 

02-32

T4NxM0

IIIB

ND

ND

ND

 

02-34

T4N2M0

IIIB

ND

ND

ND

 

02-35*

T4NxM0

IIIB

Remission

Remission

Progression. Metastases in brain

 

02-37*

T4N0M0

IIIB

Progression. Metastases in brain, lungs, liver and bones

ND

ND

 

02-38

T2N2M0

IIIA

ND

ND

ND

 

02-41

T1N1M0

IIA

Remission

Remission

Remission

 

Final outcome

Progression or death in 5 out of 11 patients (45%)

  1. Note: Cancer progression (metastatic disease or patient death) is highlighted by boldface.
  2. 1– ND – no data available.
  3. *– estrogen-dependent tumors.